A phase I-II study of COX-2 inhibitor, Celebrex (Celecoxib) and chemoradiation in patients with locally advanced cervical cancer: Primary endpoint analysis of RTOG 0128

被引：2
|
作者：
Gaffney, DK
Winter, K
Dicker, A
Miller, B
Jhingran, A
Ryu, J
Avizonis, V
Fromm, M
Greven, K
机构：
[1] Univ Utah, Salt Lake City, UT USA
[2] RTOG, Philadelphia, PA USA
[3] Thomas Jefferson Univ, Philadelphia, PA 19107 USA
[4] Wake Forest Univ, Winston Salem, NC 27109 USA
[5] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[6] Univ Calif Davis, Sacramento, CA 95817 USA
[7] LDS Hosp, Salt Lake City, UT USA
[8] Akron Gen Med Ctr, Akron, OH USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2005年 / 63卷 / 02期
关键词：
D O I：
10.1016/j.ijrobp.2005.07.161
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
155
引用
收藏
页码：S93 / S94
页数：2
相关论文
共 50 条
  • [1] A phase II study of acute toxicity for celebrex™ (celecoxib) and chemoradiation in patients with locally advanced cervical cancer:: Primary endpoint analysis of RTOG 0128
    Gaffney, David K.
    Winter, Kathryn
    Dicker, Adam P.
    Miller, Brigitte
    Eifel, Patricia J.
    Ryu, Janice
    Avizonis, Vilija
    Fromm, Mitch
    Greven, Kathryn
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 67 (01): : 104 - 109
  • [2] Celebrex™ (Celecoxib) and chemoradiation in patients with locally advanced cervical cancer.: An efficacy report of RTOG 0128
    Gaffney, D. K.
    Winter, K.
    Dicker, A. P.
    Miller, B.
    Eifel, P. J.
    Ryu, J.
    Avizonis, V.
    Fromm, M.
    Greven, K.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (03): : S41 - S41
  • [3] ERCC1, COX-2, and p53 expression in patients with locally advanced cervical cancer treated with chemoradiotherapy and celecoxib: A quantitative immunohistochemical analysis of RTOG 0128
    Doll, C. M.
    Winter, K.
    Gaffney, D. K.
    Ryu, J.
    Jhingran, A.
    Dicker, A. P.
    Weidhaas, J. B.
    Miller, B. E.
    Magliocco, A. M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01): : S355 - S356
  • [4] A COX-2 inhibitor combined with chemoradiation of locally advanced rectal cancer: a phase II trial
    Jakobsen, Anders
    Mortensen, John Ploen
    Bisgaard, Claus
    Lindebjerg, Jan
    Rafaelsen, Soren Rafael
    Bendtsen, Vagn Ove
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2008, 23 (03) : 251 - 255
  • [5] A COX-2 inhibitor combined with chemoradiation of locally advanced rectal cancer: a phase II trial
    Anders Jakobsen
    John Pløen Mortensen
    Claus Bisgaard
    Jan Lindebjerg
    Søren Rafael Rafaelsen
    Vagn Ove Bendtsen
    International Journal of Colorectal Disease, 2008, 23 : 251 - 255
  • [6] Low COX-2 Expression, But Not CD34, Predicts for Worse Overall Survival in Patients with Locally-advanced Cervical Cancer Treated with Chemoradiotherapy and Celecoxib: A Comparative Immunohistochemical Analysis of RTOG 0128
    Doll, C. M.
    Winter, K.
    Gaffney, D. K.
    Ryu, J. K.
    Jhingran, A.
    Dicker, A. P.
    Weidhaas, J. B.
    Miller, B. E.
    Diaz, R.
    Magliocco, A. M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : S150 - S151
  • [7] A Cox-2 inhibitor combined with chemoradiation of locally advanced rectal cancer
    Jakobsen, A.
    Morstensen, J.
    Bisgaard, C.
    Lindebjerg, J.
    Bendtsen, V
    Rafaelsen, S.
    ANNALS OF ONCOLOGY, 2006, 17 : 105 - 105
  • [8] A COX-2 inhibitor combined with chemoradiation of locally advanced rectal cancer
    Gurpreet Singh-Ranger
    Pasquale Giordano
    International Journal of Colorectal Disease, 2009, 24 : 863 - 863
  • [9] A COX-2 inhibitor combined with chemoradiation of locally advanced rectal cancer
    Singh-Ranger, Gurpreet
    Giordano, Pasquale
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2009, 24 (07) : 863 - 863
  • [10] Phase I-II trial of preoperative chemoradiation in locally advanced cervical carcinoma
    Mancuso, S
    Smaniotto, D
    Panici, PB
    Favale, B
    Greggi, S
    Manfredi, R
    Margariti, PA
    Morganti, AG
    Scambia, G
    Tortoreto, F
    Valentini, V
    Cellini, N
    GYNECOLOGIC ONCOLOGY, 2000, 78 (03) : 324 - 328
12345